首页> Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie> Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies.

Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Keywan,Mortezaee

第一单位： Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: mortezaee.k@muk.ac.ir.

作者： Keywan,Mortezaee ^[1] ; Jamal,Majidpoor ^[2] ; Sajad,Najafi ^[3] ; Davood,Tasa ^[4]

作者单位： Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: mortezaee.k@muk.ac.ir. ^[1] Department of Anatomy, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. ^[2] Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ^[3] Hepatopancreatobiliary Surgery Fellowship, Organ Transplantation Group, Massih Daneshvari Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Surgery, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. ^[4]

关键词 CD8(+) T cell Immune checkpoint inhibitor (ICI)Major histocompatibility complex class I (MHC-I)Programed death-1 receptor (PD-1)Programmed death-ligand 1 (PD-L1)Resistance Transforming growth factor (TGF)

医学主题词人类(Humans);生态系统(Ecosystem);肿瘤(Neoplasms);免疫疗法(Immunotherapy)

DOI 10.1016/j.biopha.2022.114150

PMID 36577330

发布时间 2023-01-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交